A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
Open Access
- 7 October 2011
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 432
Abstract
The phosphate ester PR-104 is rapidly converted in vivo to the alcohol PR-104A, a nitrogen mustard prodrug that is metabolised to hydroxylamine (PR-104H) and amine (PR-104M) DNA crosslinking agents by one-electron reductases in hypoxic cells and by aldo-keto reductase 1C3 independently of oxygen. In a previous phase I study using a q 3 week schedule of PR-104, the maximum tolerated dose (MTD) was 1100 mg/m2 and fatigue, neutropenic fever and infection were dose-limiting. The primary objective of the current study was to determine the dose-limiting toxicity (DLT) and MTD of weekly PR-104.Keywords
This publication has 24 references indexed in Scilit:
- Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104PLOS ONE, 2011
- Glucuronidation of Anticancer Prodrug PR-104A: Species Differences, Identification of Human UDP-Glucuronosyltransferases, and Implications for TherapyThe Journal of Pharmacology and Experimental Therapeutics, 2011
- The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3Cancer Research, 2010
- The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesisMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009
- Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancerJournal of Clinical Pathology, 2007
- Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxiaProceedings of the National Academy of Sciences, 2007
- Localization of cyclooxygenases-1 and -2, and prostaglandin F synthase in human kidney and renal cell carcinomaBiochemical and Biophysical Research Communications, 2005
- S‐Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP‐glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxenBritish Journal of Clinical Pharmacology, 2005
- Hypoxia as a target for combined modality treatmentsEuropean Journal of Cancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000